Pneumococcal Pneumonia and the Limits of Antimicrobial Therapy
The Journal of Infectious Diseases · 17.11.2026
DOI: 10.1093/infdis/jiag556 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 17.11.2026. Verfasst von Arturo Casadevall. Beteiligte Einrichtung: Department of Molecular Microbiology and Immunology and Division of Infectious Diseases, Johns Hopkins Bloomberg School of Public Medicine, Baltimore…. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
The mortality of pneumococcal pneumonia decreased from 30% to about 10% in the past century with the development of effective therapy, first in the form of serotherapy and then antimicrobial drugs. However, most of the progress in reducing the mortality of pneumococcal pneumonia was made in the mid-20th century, and recent decades may have witnessed some backsliding with the emergence of antimicrobial resistance and higher mortality in immunosuppressed individuals. Hence, we may be reaching the asymptote of antimicrobial efficacy, and future progress in reducing mortality could require helping the host in addition to killing the microbe.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Microbiology and Immunology and Division of Infectious Diseases, Johns Hopkins Bloomberg School of Public Medicine, Baltimore, MD, United States of America, 21205.
ORCID-Profile: Arturo Casadevall
Zitieren
APA
Casadevall, A. (2026). Pneumococcal Pneumonia and the Limits of Antimicrobial Therapy. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag556
Vancouver
Casadevall A. Pneumococcal Pneumonia and the Limits of Antimicrobial Therapy. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag556
BibTeX
@article{Casadevall2026,
author = {Casadevall, Arturo},
title = {Pneumococcal Pneumonia and the Limits of Antimicrobial Therapy},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag556}
}
EUVIMED